CD8A and neoplasm: And when in combination with ICIs, it can lessen the drug resistance problem of “cold tumors” (71), which were defined as no or very little infiltration of CD3+ and CD8+ lymphocytes in the center and border area of the tumor, such as prostate cancer (72).